International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients
Authors:
- de LigtDLde Ligt
- K. M.KMK. M.
- B. H.BHB. H.
Open Access
- 20 January 2023
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 265-281
Abstract
Purpose: For patients living with metastatic breast cancer (MBC), achieving best possible health-related quality of life, along with maximizing survival, is vital. Yet, we have no systemic way to determine if we achieve these goals. A Core Outcome Set (COS) that allows standardized measurement of outcomes important to patients, but also promotes discussing these outcomes during clinical encounters, is long overdue. Methods: An international expert group (EG) of patient advocates, researchers, medical specialists, nurse specialists, and pharmaceutical industry representatives (n = 17) reviewed a list of relevant outcomes retrieved from the literature. A broader group (n = 141: patients/patient advocates (n = 45), health care professionals/researchers (n = 64), pharmaceutical industry representatives (n = 28), and health authority representatives (n = 4)) participated in a modified Delphi procedure, scoring the relevance of outcomes in two survey rounds. The EG finalized the COS in a consensus meeting. Results: The final MBC COS includes 101 variables about: (1) health-related quality of life (HRQoL, n = 26) and adverse events (n = 24); (2) baseline patient characteristics (n = 9); and (3) clinical variables (n = 42). Many outcome that cover aspects of HRQoL relevant to MBC patients are included, e.g. daily functioning (including ability to work), psychosocial/emotional functioning, sexual functioning, and relationship with the medical team. Conclusion: The COS developed in this study contains important administrative data, clinical records, and clinician-reported measures that captures the impact of cancer. The COS is important for standardization of clinical research and implementation in daily practice and has received accreditation by the International Consortium for Health Outcomes Measurement (ICHOM).Keywords
Funding Information
- Innovative Medicines Initiative 2 Joint Undertaking (945345-2)
This publication has 30 references indexed in Scilit:
- Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User SurveyPLOS ONE, 2016
- What Is the Value of the Routine Use of Patient-Reported Outcome Measures Toward Improvement of Patient Outcomes, Processes of Care, and Health Service Outcomes in Cancer Care? A Systematic Review of Controlled TrialsJournal of Clinical Oncology, 2014
- Challenges to the early diagnosis and treatment of breast cancer in developing countriesWorld Journal of Clinical Oncology, 2014
- Informational Needs of Patients with Metastatic Breast Cancer: What Questions Do They Ask, and Are Physicians Answering Them?Journal of Cancer Education, 2013
- Core Domains for a Person-Focused Outcome Measurement System in Cancer (PROMS-Cancer Core) for Routine Care: A Scoping Review and Canadian Delphi ConsensusValue in Health, 2013
- Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic ReviewPLOS ONE, 2011
- GRADE guidelines: 2. Framing the question and deciding on important outcomesJournal of Clinical Epidemiology, 2011
- All That HoldsJournal of Holistic Nursing, 2008
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005
- Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled TrialJournal of Clinical Oncology, 2004